Industry news
Depomed board of directors rejects Horizon Pharma offer
Horizon Pharma seeks to buy Depomed Inc., and its offer has been rejected by the Depomed board of directors as being at an undervalue. Horizon is now asking Depomed to convene a shareholders meeting to vote on its offer. Depomed considers that having recently acquired US rights to Nucynta (tapentadol extended release) from Johnson & Johnson it is better off alone.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
